A hypoallergenic variant of the major birch pollen allergen shows distinct characteristics in antigen processing and T-cell activation

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 67, Issue 11, 2012, Pages 1375-1382

  Kitzmuller C ^a   Wallner, M ^b   Deifl, S ^a   Mutschlechner, S ^a   Walterskirchen, C ^a   Zlabinger, G J ^c   Ferreira, F ^b   Bohle, B ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF SALZBURG   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

allergen specific immunotherapy; Bet v 1; hypoallergen; T cell modulation

Indexed keywords

HYPOALLERGENIC MAJOR BIRCH POLLEN ALLERGEN; INTERLEUKIN 5; POLLEN ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN PRESENTATION; ARTICLE; CELL CLONE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOCYTOSIS; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLARIZATION; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ALLERGENS; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGENS, PLANT; BETULA; CELL POLARITY; HUMANS; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; POLLEN; T-LYMPHOCYTES;

EID: 84867518092     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12016     Document Type: Article

References (32)

1. Geroldinger-Simic M, Zelniker T, Aberer W, Ebner C, Egger C, Greiderer A, et al. Birch pollen-related food allergy: clinical aspects and the role of allergen-specific IgE and IgG(4) antibodies. J Allergy Clin Immunol 2011; 127: 616-622. e611.
2. Eriksson NE,. Allergy to pollen from different deciduous trees in Sweden. An investigation with skin tests, provocation tests and the radioallergosorbent test (RAST) in springtime hay fever patients. Allergy 1978; 33: 299-309.
3. Eriksson NE, Formgren H, Svenonius E,. Food hypersensitivity in patients with pollen allergy. Allergy 1982; 37: 437-443.
4. Swoboda I, Jilek A, Ferreira F, Engel E, Hoffmann-Sommergruber K, Scheiner O, et al. Isoforms of Bet v 1, the major birch pollen allergen, analyzed by liquid chromatography, mass spectrometry, and cDNA cloning. J Biol Chem 1995; 270: 2607-2613.
5. Erler A, Hawranek T, Kruckemeier L, Asam C, Egger M, Ferreira F, et al. Proteomic profiling of birch (Betula verrucosa) pollen extracts from different origins. Proteomics 2011; 11: 1486-1498.
6. Himly M, Nony E, Chabre H, Van Overtvelt L, Neubauer A, van Ree R, et al. Standardization of allergen products: 1. Detailed characterization of GMP-produced recombinant Bet v 1.0101 as biological reference preparation. Allergy 2009; 64: 1038-1045.
7. Gajhede M, Osmark P, Poulsen FM, Ipsen H, Larsen JN, Joost van Neerven RJ, et al. X-ray and NMR structure of Bet v 1, the origin of birch pollen allergy. Nat Struct Biol 1996; 3: 1040-1045.
8. Dall'Antonia F, Gieras A, Devanaboyina SC, Valenta R, Keller W,. Prediction of IgE-binding epitopes by means of allergen surface comparison and correlation to cross-reactivity. J Allergy Clin Immunol 2011; 128: 872-879 e878.
9. Gieras A, Cejka P, Blatt K, Focke-Tejkl M, Linhart B, Flicker S, et al. Mapping of conformational IgE epitopes with peptide-specific monoclonal antibodies reveals simultaneous binding of different IgE antibodies to a surface patch on the major birch pollen allergen, Bet v 1. J Immunol 2011; 186: 5333-5344.
10. Holm J, Ferreras M, Ipsen H, Wurtzen PA, Gajhede M, Larsen JN, et al. Epitope grafting, re-creating a conformational Bet v 1 antibody epitope on the surface of the homologous apple allergen Mal d 1. J Biol Chem 2011; 286: 17569-17578.
11. Jahn-Schmid B, Radakovics A, Luttkopf D, Scheurer S, Vieths S, Ebner C, et al. Bet v 1 142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1-related food allergens. J Allergy Clin Immunol 2005; 116: 213-219.
12. Larche M, Akdis CA, Valenta R,. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006; 6: 761-771.
13. Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008; 122: 951-960.
14. Valenta R, Linhart B, Swoboda I, Niederberger V,. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens. Allergy 2011; 66: 775-783.
15. Vanek-Krebitz M, Hoffmann-Sommergruber K, Laimer da Camara Machado M, Susani M, Ebner C, Kraft D, et al. Cloning and sequencing of Mal d 1, the major allergen from apple (Malus domestica), and its immunological relationship to Bet v 1, the major birch pollen allergen. Biochem Biophys Res Commun 1995; 214: 538-551.
16. Radauer C, Lackner P, Breiteneder H,. The Bet v 1 fold: an ancient, versatile scaffold for binding of large, hydrophobic ligands. BMC Evol Biol 2008; 8: 286.
17. Wallner M, Hauser M, Himly M, Zaborsky N, Mutschlechner S, Harrer A, et al. Reshaping the Bet v 1 fold modulates T(H) polarization. J Allergy Clin Immunol 2011; 127: 1571-1578. e1579.
18. Mutschlechner S, Egger M, Briza P, Wallner M, Lackner P, Karle A, et al. Naturally processed T cell-activating peptides of the major birch pollen allergen. J Allergy Clin Immunol 2010; 125: 711-718, 718 e711-718, e712.
19. Egger M, Jurets A, Wallner M, Briza P, Ruzek S, Hainzl S, et al. Assessing protein immunogenicity with a dendritic cell line-derived endolysosomal degradome. PLoS ONE 2010; 6: e17278.
20. Delamarre L, Pack M, Chang H, Mellman I, Trombetta ES,. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science 2005; 307: 1630-1634.
21. Fritsch R, Bohle B, Vollmann U, Wiedermann U, Jahn-Schmid B, Krebitz M, et al. Bet v 1, the major birch pollen allergen, and Mal d 1, the major apple allergen, cross-react at the level of allergen-specific T helper cells. J Allergy Clin Immunol 1998; 102: 679-686.
22. Smole U, Wagner S, Balazs N, Radauer C, Bublin M, Allmaier G, et al. Bet v 1 and its homologous food allergen Api g 1 stimulate dendritic cells from birch pollen-allergic individuals to induce different Th-cell polarization. Allergy 2010; 65: 1388-1396.
23. Verhasselt V, Buelens C, Willems F, De Groote D, Haeffner-Cavaillon N, Goldman M,. Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells: evidence for a soluble CD14-dependent pathway. J Immunol 1997; 158: 2919-2925.
24. Cromwell O, Hafner D, Nandy A,. Recombinant allergens for specific immunotherapy. J Allergy Clin Immunol 2011; 127: 865-872.
25. Vrtala S, Hirtenlehner K, Vangelista L, Pastore A, Eichler HG, Sperr WR, et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest 1997; 99: 1673-1681.
26. Ferreira F, Ebner C, Kramer B, Casari G, Briza P, Kungl AJ, et al. Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. FASEB J 1998; 12: 231-242.
27. Vrtala S, Fohr M, Campana R, Baumgartner C, Valent P, Valenta R,. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination. Vaccine 2011; 29: 2140-2148.
28. Campana R, Vrtala S, Maderegger B, Jertschin P, Stegfellner G, Swoboda I, et al. Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly. J Allergy Clin Immunol 2010; 126: 1024-1031, 1031 e1021-1028.
29. Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P, et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004; 101 (Suppl 2): 14677-14682.
30. Purohit A, Niederberger V, Kronqvist M, Horak F, Gronneberg R, Suck R, et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 2008; 38: 1514-1525.
31. Constant S, Pfeiffer C, Woodard A, Pasqualini T, Bottomly K,. Extent of T cell receptor ligation can determine the functional differentiation of naive CD4+ T cells. J Exp Med 1995; 182: 1591-1596.
32. Akdis CA, Blesken T, Wymann D, Akdis M, Blaser K,. Differential regulation of human T cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants. Eur J Immunol 1998; 28: 914-925.